ATAGI and the Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) have released a joint statement surrounding the administration of COVID-19 AstraZeneca and Thrombosis with Thrombocytopenia Syndrome (TTS).

Following close monitoring of local and international data it has been noted that the risk of TTS is not likely to be increased in people who:

  • Have a history of blood clots in typical sites
  • Have an increased clotting tendency that is not immune mediated
  • Have a family history of blood clots
  • Have a history of ischaemic heart disease
  • Currently have or has a history of thrombocytopenia
  • Are receiving anticoagulation therapy

Comirnaty™ is the preferred COVID-19 vaccine for people who:

  • Have a history of idiopathic splanchnic vein thrombosis
  • Have a history of antiphospholipid syndrome with thrombosis
  • Individuals < 50 years of age
  • Have a history of cerebral venous sinus thrombosis (CVST)
  • Have a history of heparin-induced thrombocytopenia (HIT)
  • Have a contraindication to COVID-19 AstraZeneca (including anaphylaxis to a previous dose or anaphylaxis to a component of COVID-19 AstraZeneca, TTS occurring after a dose of COVID-19 AstraZeneca or other serious adverse event following receipt of COVID-19 AstraZeneca)

To read the statement in full please refer to the following link:

Joint statement from ATAGI and THANZ on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of COVID-19 Vaccine AstraZeneca